Circulating DNA in the neoadjuvant setting of early stage colon cancer

Figures & data

Table 1. Multivariable analysis for disease-free survival^a.

	P-value	HR	95% CI HR
			Lower	Upper
Pathological stage (I/II vs III)	0.069	2.692	0.925	7.833
ECOG PS (0 vs 1)	0.484	0.666	0.213	2.080
Baseline CEA (<3 vs ≥ 3)	0.185	1.915	0.733	5.003
Baseline cfDNA (<1100 ng/ml vs ≥ 1100 ng/ml)	0.027	3.351	1.149	9.767
Relative change of cfDNA from baseline to surgery (<18% vs ≥ 18%)	0.067	2.568	0.936	7.045

CI: Confidence interval; HR: Hazard ratio; ng/ml: nanogram/milliliter.

^aThe ‘sex’ variable was excluded from the analysis since no survival events occurred in the female group.

All variables were entered in the model as categorical.

Figure 1. Study flow diagram.

Figure 2. Disease-free survival (A) and overall survival (B) by baseline cfDNA.

Figure 3. Disease-free survival by cfDNA (A) and ctDNA (B) relative changes from baseline to surgery.

Figure 4. Disease-free survival (A) and overall survival (B) by baseline ctDNA.